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Mycophenolate mofetil prevents the development of glomeru- The pathogenesis of diabetic nephropathy involves
lar injury in experimental diabetes. both metabolic [1] and hemodynamic factors [2]. In addi-
Background. Experimental and clinical evidence suggests tion, abundant in vivo [3] and in vitro [4, 5] evidence nowthat inflammation plays a role in the pathogenesis of diabetic
indicates that inflammatory phenomena are necessary tonephropathy, in addition to, or in concert with, the associated
translate these primary insults into chronic progressivehemodynamic and metabolic changes. The present study as-
sessed the effects of chronic anti-inflammatory therapy in ex- renal disease.
perimental diabetic nephropathy. The advent of angiotensin-converting enzyme (ACE)
Methods. Adult male Munich-Wistar rats were made diabetic inhibitors and angiotensin II receptor blockers has changed
with streptozotocin after uninephrectomy, kept moderately hy- profoundly the therapeutic approach to diabetic nephrop-perglycemic by daily injections of NPH insulin and distributed
athy, and may improve the survival and the quality of lifeamong three groups: C, non-diabetic rats; DM, rats made dia-
of diabetic patients significantly [6–8]. However, the obser-betic and treated with insulin as described earlier; and DM
MMF, diabetic rats receiving insulin and treated with mycophe- vation that a substantial fraction of diabetic subjects re-
nolate mofetil (MMF), 10 mg/kg once daily by gavage. Renal sponds poorly to these treatments [6–8] underscores the
hemodynamic studies were performed 6 to 8 weeks after induc- need for additional therapeutic maneuvers capable of halt-
tion of diabetes. Additional rats were followed during 8 months,
ing the progression to end-stage renal failure.at the end of which renal morphological studies were performed.
Recent studies have shown evidence that treatmentsResults. After 6 to 8 weeks, diabetic rats exhibited marked
glomerular hyperfiltration and hypertension. Diabetic rats de- aimed at limiting renal inflammation can largely attenu-
veloped progressive albuminuria and exhibited widespread glo- ate renal injury in experimental models of progressive
merulosclerotic lesions associated with macrophage infiltration renal disease [9–11]. We have shown that renal injury as-
at 8 months. Treatment with MMF had no effect on blood pres- sociated with 5/6 renal ablation (Nx), a well-known modelsure, glomerular dynamics or blood glucose levels, but did pre-
of progressive nephropathy, was strongly limited by treat-vent albuminuria, glomerular macrophage infiltration and glo-
ment with a non-steroidal anti-inflammatory drug [9].merulosclerosis. Thus, the renoprotective effect of MMF was
not associated with a metabolic or renal hemodynamic effect, Similar protection was obtained when Nx rats were treated
and must have derived from its well-known anti-inflammatory with mycophenolate mofetil (MMF), an anti-lymphocyte
properties, which include restriction of lymphocyte and macro- drug with immunosuppressive/anti-inflammatory prop-
phage proliferation and limitation of the expression of adhesion erties [10, 11] and widely used in recent years to preventmolecules.
allograft rejection [12]. The association of MMF with anConclusions. These findings are consistent with the notion
angiotensin II receptor blocker affords superior protec-that inflammatory events are central to the pathogenesis of
diabetic nephropathy and suggest that MMF may help prevent tion [13, 14], even when started after renal injury is al-
the progression of diabetic nephropathy. ready established [13].
In the present study, we evaluated the anti-inflamma-
tory and hemodynamic effects of MMF administration to1 See Editorial by Meyer, p. 377.
streptozotocin diabetic rats. In addition, we investigated
Key words: renoprotection, diabetic nephropathy, inflammation, anti- whether early MMF treatment can prevent the progres-
inflammatory drugs, glomerulosclerosis, progressive renal disease, end- sive glomerulopathy associated with this model.
stage renal failure, albuminuria.
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were used in this study. All rats were subjected to right ously, with measurement of the respective 14C activities
nephrectomy under anesthesia with sodium pentobarbi- and calculation of renal inulin extraction. Blood samples
tal (50 mg/kg IP) to hasten the development of diabetic were obtained from the renal vein with a glass micro-
glomerulopathy as described previously [15, 16], and pipette, 40 to 45 m OD. Plasma and urine 14C activities
were rendered diabetic three weeks later by streptozo- were determined in a scintillation counter (Beckman
tocin 65 mg/kg IV (Sigma Chemical Co., St. Louis, MO, Instruments, Schiller Park, IL, USA). Renal plasma flow
USA). Diabetes was confirmed two days later by reflec- (RPF) was calculated as RPF  GFR/FF, where GFR
tometric measurement of tail blood glucose concentra- represents the glomerular filtration rate and FF is the
tion (BG). Diabetic rats received daily injections of NPH filtration fraction. Renal vascular resistance (RVR) was
insulin, in doses adjusted individually (ranging from 1 to calculated by the expression RVR  MAP · (1-Hct)/
4 units) to maintain BG levels between 200 and 400 mg/dL. RPF, where MAP and Hct represent mean arterial pres-
BG levels were measured twice a week. All animals re- sure and arterial hematocrit, respectively. At the end of
ceived standard rat chow (Harlan Teklad, Madison, WI, each experiment, the renal tissue was perfusion-fixed for
USA) with 25% of protein. MMF (Roche Laboratories, histologic and immunohistochemical analysis (described
Nutley, NJ, USA) was dissolved in dimethylsulfoxide (5%) later in this article).
and then in olive oil [10], and given by gavage at 10 mg/
kg/day. In preliminary experiments, this was found to be Long-term studies
the maximum dose that the rats would tolerate without
Six C, eight DM and nine DMMMF rats were fol-losing weight or showing deterioration of their general
lowed until eight months after induction of diabetes, withcondition. MMF was given by gavage daily in a volume
bi-monthly determination of tail-cuff pressure (TCP) andof vehicle not exceeding 0.4 mL. All experimental proce-
albumin excretion rate (UAlbV). At the end of the study,dures were conducted in accordance with local institu-
rats were anesthetized with sodium pentobarbital 50tional guidelines.
mg/kg IP. The left kidney was then perfusion-fixed in
Experimental groups situ, at the measured arterial pressure, with Dubosq-
Brazil solution after a brief washout with saline. AfterThree experimental groups were studied: C, non-dia-
perfusion-fixation, the kidney was weighed and twobetic uninephrectomized rats; DM, uninephrectomized
midcoronal sections were fixed in buffered 10% formal-rats made diabetic and treated with insulin according to
dehyde solution. The material then was embedded inthe procedures described earlier; DMMMF, unineph-
rectomized diabetic rats receiving insulin and MMF as paraffin for assessment of glomerular injury, as well as
described earlier. for immunohistochemical detection of macrophages.
B
Histomorphometry
Renal hemodynamic studies Sections 2 to 3 m thick were stained with the periodic
To evaluate renal functional parameters, seven rats of acid-Schiff reaction. The average glomerular tuft volume
each group were subjected to micropuncture experiments (VG) at six to eight weeks of diabetes was estimated as
six to eight weeks after induction of diabetes. Rats were described previously [17]. The extent of glomerulosclero-
anesthetized with Inactin (100 mg/kg, IP) and placed on sis was evaluated by calculating a glomerulosclerosis in-
a temperature-regulated table. The femoral artery was dex (GSI) as described previously [13]. A pathologist
catheterized to determine baseline hematocrit, for peri- blinded to the origin of the animals examined at least
odic blood sampling, and for continuous monitoring of 200 glomeruli for each rat.
mean arterial pressure with a pressure transducer con-
nected to a computerized data acquisition device (Dataq Immunohistochemical analysis
Instruments, Akron, OH, USA). Surgical fluid losses were
Macrophages and lymphocytes were detected in 4-m-compensated by an intravenous infusion of homologous
thick paraffin-embedded renal sections as described else-plasma. Saline solution containing 14C-carboxylated inu-
where [13]. For immunostaining of macrophages and lym-lin (0.3 Ci/mL) was infused at 1.5 mL/h. The kidney
phocytes, monoclonal anti-ED-1 (Serotec, Oxford, UK)was properly immobilized and continuously bathed with
and anti-CD-3 (Sera-Lab, Loughborough, UK) antibodiesisotonic saline. After two hours of anesthesia, urine was
were used. Quantitative analysis of ED-1–positive cellscollected from the ureter during 20 minutes for measure-
was performed in a blinded fashion under250 magnifi-ment of flow rate and inulin concentration. Hydraulic
cation and expressed as cells/glomerular cross sectionpressures in superficial glomeruli (PGC), tubules, and ef-
(gcs). For each section, 50 sequential glomerular profilesferent arterioles were measured with a servo-nulling de-
were examined. For quantification of CD-3 cells, 25 mi-vice (Model V; Instrumentation for Physiology and Med-
croscopic fields, each corresponding to an area of 0.06icine, San Diego, CA, USA). Whole-kidney filtration
mm2 (250), were examined. The results were expressedfraction (FF) was determined by collecting blood sam-
ples from the renal vein and femoral artery simultane- in cells/mm2.
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Table 1. Functional parameters at six to eight weeks after diabetes
RVRBW KW GFR RPF
BG MAP mm Hg/ PGC VG
Group g mg/dL mm Hg mL/min mL/min mm Hg 106 lm3
C 34710 2.30.1 883 1242 1.60.1 6.70.5 11.51.4 531 1.120.08
DM 3135a 3.40.1a 40212a 1194 2.70.1a 9.50.4a 6.90.4a 643a 1.330.07
DMMMF 3084a 2.70.1ab 38218a 1234 2.40.1a 9.90.7a 7.60.4a 632a 1.040.06b
Values are presented as mean  SE. Abbreviations are: BW, body weight; KW, kidney weight; MAP, mean arterial pressure; GFR, glomerular filtration rate;
RPF, renal plasma flow; RVR, renal vascular resistance; PGC, glomerular capillary pressure; VG, glomerular volume. N  7/group.
a P  0.05 vs. C
b P  0.05 vs. DM
Statistics significantly (1.04  0.06 106 m3, P  0.05 vs. DM
and P 0.05 vs. C). No glomerulosclerosis was detectedOne-way analysis of variance (ANOVA) with pair-
in any of the groups at this time.wise comparisons according to the Tukey method was
used in this study. Since GSI and UAlb followed a non- Long-term studies
normal distribution, log transformation was performed
Body growth was retarded in diabetic compared toprior to statistical analysis of these parameters. The Spear-
non-diabetic rats. MMF treatment promoted no furtherman r coefficient was calculated to assess the correlations
stunting of body growth (Fig. 1A). BG was maintainedbetween GSI, albuminuria and the intensity of glomeru-
at similar levels (between 200 and 400 mg/dL) in un-lar macrophage infiltration. P levels of 0.05 or less were
treated and MMF-treated diabetic rats throughout theconsidered significant.
study (Fig. 1B). TCP was similar among groups (data
not shown). Albumin excretion rate increased steadily
RESULTS with time in DM rats, reaching values almost threefold
Renal hemodynamic studies higher than in non-diabetic controls at eight months after
diabetes induction (Fig. 1C). MMF treatment dramati-Renal and systemic functional and hemodynamic pa-
cally reduced albuminuria, which remained at levels simi-rameters 6–8 weeks after diabetes induction are given
lar to controls in Group DMMMF throughout thein Table 1. Body weight (BW) was lower in Groups DM
study (Fig. 1C).and DMMMF compared to C, whereas MAP values
were similar among groups. As shown previously, diabe-
Renal histology and immunohistochemistrytes promoted renal enlargement (3.4  0.1 g in Group
Almost no glomerular injury was seen in control non-DM vs. 2.3  0.1 g in C, P  0.05). Treatment with
diabetic rats at eight months (Fig. 2A). Glomerulosclero-MMF attenuated renal hypertrophy in Group DM
tic lesions, consisting of focal and segmental areas ofMMF (2.7 0.1 g, P 0.05 vs. C and DM). A prominent
mesangial expansion, collapse of capillary loops and for-elevation of GFR was observed in Group DM (2.7 
mation of synechiae with Bowman’s capsule were promi-0.1 vs. 1.6 0.1 mL/min in C, P 0.05). The administra-
nent in DM rats (Fig. 2B). The glomerulosclerosis indextion of MMF promoted no significant change in GFR
(GSI) was almost tripled in Group DM compared to C(2.4  0.1 mL/min, P  0.05 vs. DM and P  0.05 vs.
(14  4 vs. 5  1, respectively, P  0.05; Fig. 4). MMFGroup C). Likewise, RPF was augmented in diabetic
completely prevented the development of glomerularrats (9.5  0.4 in Group DM vs. 6.7  0.5 mL/min in
lesions in Group DMMMF (Fig. 2C), in which GSIGroup C, P  0.05). RPF remained abnormally high in
remained close to control (4  1, P  0.05 vs. Group CMMF-treated rats (9.9  0.7 mL/min in Group DM
and P  0.05 vs. DM).MMF, P  0.05 vs. DM and P  0.05 vs. C). RVR was
A significant increase in the density of ED-1–positivedecreased in diabetic rats (6.9  0.4 in Group DM vs.
cells in the glomerular area was observed in Group DM11.5  1.4 mm Hg/mL/min in C, P  0.05) and was
after two months (2.6  0.3 cells/gcs in Group DM vs.unchanged by MMF treatment (7.6  0.4 mm Hg/mL/
1.4 0.1 in Group C, P 0.05) and eight months (3.1min in Group DMMMF, P  0.05 vs. DM and P 
0.6 cells/gcs in Group DM vs. 0.9  0.2 in Group C, P 0.05 vs. C). Glomerular hydraulic pressure was markedly
0.05; Fig. 5) of study. Nearly all ED-1–positive cells wereelevated in Group DM compared to C (64  3 vs. 53 
located in glomerular tufts (Fig. 3). MMF treatment pre-1 mm Hg, P  0.05). MMF promoted no change in PGC
vented macrophage infiltration in Group DMMMF at(63  2 mm Hg in DMMMF, P  0.05 vs. DM and
two months (1.4 0.1 cells/gcs, P 0.05 vs. Group C andP  0.05 vs. C). Glomerular volumes were numerically
P  0.05 vs. DM) and eight months of diabetes (1.4 increased in DM (1.33  0.07 vs. 1.12  0.08  106 m3
in C, P  0.05). MMF treatment reduced VG slightly but 0.3 cells/gcs in Group DMMMF, P  0.05 vs. Group C
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Fig. 1. Body weight (A), blood glucose concentration (B) and urine albumin excretion rate (C ) as a function of time in the control (C; ), diabetes
mellitus (DM; ) and DM  mycophenolate mofetil (MMF; ) gorups. Error bars represent SE. aP  0.05 vs. C; bP  0.05 vs. DM.
and P  0.05 vs. DM; Fig. 5). Lymphocytes were ob- tant protein-1 (MCP-1) [21], vascular endothelial growth
factor [22] and components of the renin-angiotensin sys-served only in the interstitial area. No differences in
lymphocyte density were detected among groups at ei- tem [23], all of which may contribute to intensify and
propagate inflammation. Mechanically induced inflam-ther two months (data not shown) or eight months of
diabetes (Fig. 6). A significant linear correlation (r 2  mation is facilitated also by the increased expression of
adhesion molecules such as intercellular adhesion mole-0.49, P  0.001) was observed between GSI and the
density of glomerular macrophages (Fig. 7). A positive cule (ICAM-1) [24]. Podocytes also may be affected by
mechanical stress, which was shown to alter their cy-correlation was found also between GSI and UAlbV (r 2 
toskeleton properties [25] and reduce their proliferative0.55, P  0.001) and between UAlbV and glomerular
capability [26]; these actions can lead to the formationmacrophage infiltration (r 2  0.48, P  0.001).
of adhesions between the tuft and the parietal layer of
Bowman’s capsule, and thus to the development of GS.
DISCUSSION Expansion of the glomerular tuft, such as observed in
As expected, diabetic rats exhibited progressive albu- this study, may have contributed to the aggravation of
minuria and focal and segmental glomerulosclerosis, con- the mechanical tension imposed to the capillary wall, as
sisting of diffuse mesangial widening and formation of predicted by the La Place relationship [27], although the
synechiae between the tuft and the parietal layer of Bow- changes in glomerular volume observed in this study
man’s capsule (Fig. 2B), in contrast with the virtual ab- were only modest.
sence of glomerulopathy in non-diabetic controls (Fig. 2A). Glomerular mechanical injury can be facilitated in dia-
Glomerular capillary hypertension was readily observed betic subjects, since many of these changes can be exacer-
in diabetic rats and likely played a role in the develop- bated in a hyperglycemic ambient [5]. Nevertheless, in-
ment of glomerular injury in these animals [2, 16]. Al- flammatory phenomena may be directly triggered by
though the exact mechanisms by which glomerular hy- hyperglycemia, independently from mechanical strain,
pertension promotes glomerular injury are incompletely since mesangial cells cultivated at high glucose concen-
understood, a large number of studies now indicate that trations with no stretch produce excessive amounts of
mechanical stretching of the glomerular wall induces MCP-1 [4]. In addition, persistent hyperglycemia leads
profound phenotypic changes in glomerular cells. In vitro to the well-known formation of AGEs [28], which can
stretching of mesangial cells has been shown to stimulate favor the development of diabetic nephropathy by at
mitosis and prostanoid synthesis [18], as well as the pro- least two mechanisms: (1) direct alteration of vascular
structures by formation of cross-links between collagenduction of collagen [18] and other components of the
extracellular matrix such as laminin and fibronectin [19]. molecules [28]; (2) binding of glycated molecules to spe-
cific AGE receptors (RAGEs) on the surface of mesan-In addition, mesangial stretching stimulates the synthesis
of cytokines and growth factors such as transforming gial cells, leading to chronic inflammation by excessive syn-
thesis of cytokines and extracellular matrix proteins [29].growth factor- (TGF-) [20], monocyte chemoattrac-
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such as TGF- [33], nitric oxide [34] and tumor necrosis
factor [35], thus recruiting additional inflammatory cells
that may contribute to the propagation of inflammation
and GS. In the present study, macrophage infiltration, af-
fecting almost exclusively the glomeruli, was evident at
both early (2 months) and late (8 months) stages of the
disorder, mostly in the glomerular area (Fig. 3). The in-
tensity of the macrophage infiltration correlated strongly
with the GSI at eight months (Fig. 7). Since at two months
of diabetes glomerular injury was essentially absent, these
observations, taken as a whole, suggest that macrophage
infiltration, which anteceded the development of glomer-
ular injury, is a key intermediary event in the pathogene-
sis of GS in this model. This interpretation is consistent
with the findings of Sassy-Prigent and coworkers [36],
who showed that macrophage depletion by previous irra-
diation prevented glomerular enlargement and glomeru-
losclerosis in experimental diabetes.
The pharmacological treatment of diabetic glomerulo-
pathy has consisted mostly in the administration of ACE
inhibitors and, more recently, angiotensin II type 1 (AT-1)
receptor blockers. These compounds are believed to act
basically by lowering glomerular pressure, although mount-
ing evidence indicates that angiotensin II (Ang II) may
have several non-hemodynamic effects that favor inflam-
mation [37]. In the present study, MMF, an immunosup-
pressive anti-inflammatory drug with no effect on glomer-
ular hemodynamics, was used to our knowledge for the
first time to prevent diabetic glomerulopathy. As in the
renal ablation model [10, 11], MMF prevented the devel-
opment of albuminuria and glomerular injury in diabetic
rats, which were reduced to levels indistinguishable from
those seen in age-matched non-diabetic controls. In addi-
tion, MMF entirely prevented renal and, particularly, glo-
merular enlargement. This is in contrast with the lack of
effect of MMF on renal weight or glomerular volume in
the renal ablation model [10]. The reason for this dis-
crepancy is unclear. However, it should be noted that
macrophage depletion, such as observed in the present
study in MMF-treated rats, was shown to prevent glo-
merular expansion in experimental diabetes [36]. More-Fig. 2. Representative glomeruli in control (A), DM (B) and DM
MMF (C ) rats. (Periodic acid-Schiff staining, original magnification over, most histologic/inflammatory renal changes observed
200). in diabetic rats occurred in the glomerular area, again
in contrast with the remnant kidney, in which interstitial
injury is much more prominent [10]. This helps to explain
why renal enlargement was limited in the present studyIn view of the large number of mechanical and bio-
chemical mechanisms capable of triggering chronic in- compared with observations in the remnant kidney [10, 13],
since the glomeruli correspond to only 10 to 15% of theflammation, it is hardly surprising that subjects with dia-
betic nephropathy exhibit many signs of inflammation in total renal volume. Interestingly, prevention of glomeru-
lar expansion by MMF was not accompanied by a glo-the renal tissue. Several studies of human [30] and experi-
mental [31] diabetic nephropathy reported the presence merular filtration rate (GFR) limitation, even though PGC
remained elevated in treated animals. Although the rea-of macrophage infiltration, as well as increased expression
of adhesion molecules, in the renal parenchyma. Macro- son for this apparent paradox is not readily apparent, it
must be noted that the filtration surface is not necessarilyphages can be attracted/activated directly by mechanical
stress [21, 32], and may produce inflammatory mediators proportional to glomerular volume in diabetic subjects
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Fig. 4. Glomerulosclerosis index (GSI) in the C, DM and DMMMF
groups. Values are presented as mean  1 SE; *P  0.05 vs. C; †P 
0.05 vs. DM.
Fig. 5. Macrophage density in the glomerular area in the C, DM and
DMMMF at two months () and eight months (). Values are pre-
sented as mean  1 SE. *P  0.05 vs. C; †P  0.05 vs. DM for the
same time point.
a better metabolic control seems equally unlikely, since
BG levels remained similar between untreated and
MMF-treated diabetic rats along the entire study. There-
fore, the protective effect of MMF observed in the pres-
ent study must have resulted directly from its well-known
immunosuppressive/anti-inflammatory properties, which
derive from guanine 5	-triphosphate (GTP) depletion in
Fig. 3. Macrophages identified by ED-1 monoclonal antibody immuno- target cells. The main effect of MMF is a relatively selec-
staining in the glomerular area (indicated by the arrows) in control (A),
tive inhibition of lymphocyte proliferation [39], sinceDM (B), and DMMMF (C ) rats. (Original magnification 400).
DNA synthesis in these cells is more critically dependent
on MMF-sensitive GTP pools. We were unable to dem-
onstrate a significant degree of renal lymphocyte infil-
[38], probably because glomerular hypertrophy in diabe- tration at either two or eight months of diabetes. This is
tes results largely from expansion of the mesangial area, in agreement with the observations of Sugimoto et al at
whose dimensions are unrelated to the filtration surface. six months of diabetes [31]. However, these same inves-
As in the studies involving the 5/6 renal ablation model tigators did report renal lymphocyte infiltration at two
[10, 11], the beneficial effects of MMF in diabetic rats to four weeks of diabetes [31], suggesting that these cells
cannot be ascribed to amelioration of glomerular hyper- may play an important role at earlier phases of diabetic
tension, which was similar in untreated and MMF-treated nephropathy.
diabetic rats. MMF may have exerted a favorable effect The effects of MMF treatment in diabetic rats, pre-
by preventing glomerular tuft expansion in treated dia- venting glomerular macrophage infiltration and glomer-
betic rats, although, as discussed earlier, the magnitude ulosclerosis, may have been partially or totally indepen-
of the glomerular tuft increase observed in diabetic rats dent from any antilymphocytic action. MMF has been
reported to limit macrophage [40] and mesangial cell [41]was modest (18%). A salutary effect of MMF based on
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Fig. 7. GSI exhibited significant linear correlation with the density of
macrophages in the glomerular area (r 2  0.49, P  0.001).
Fig. 6. Lymphocyte density in the renal cortex at eight months in the
C, DM and DMMMF groups.
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